Disease-modifying therapies and infectious risks in multiple sclerosis
The DOI matches its Crossref record; 184 of the 184 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
Self-citationNew Multiple Sclerosis Phenotypic Classification
Lublin, F. D. (2014) · European Neurology · doi:10.1159/000367614 · Cited by 4,259
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,386
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Kappos, L., Radue, E.-W., O'Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K., Agoropoulou, C., Leyk, M., Zhang-Auberson, L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909494 · Cited by 2,644
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1
Matloubian, M., Lo, C. G., Cinamon, G., Lesneski, M. J., Xu, Y., Brinkmann, V., Allende, M. L., Proia, R. L., & Cyster, J. G. (2004) · Nature · doi:10.1038/nature02284 · Cited by 2,581
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., Fischer, J. S., Goodkin, D. E., Granger, C. V., Simon, J. H., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390304 · Cited by 2,450
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Cohen, J. A., Barkhof, F., Comi, G., Hartung, H.-P., Khatri, B. O., Montalban, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907839 · Cited by 2,204
Self-citationThe IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.655 · Cited by 2,085
Ebers, G. C. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03334-0 · Cited by 2,073
(2012) · Hepatogastroenterology · doi:10.5754/hge12458 · Cited by 1,977
Johnson, K. P., Brooks, B. R., Cohen, J. A., Ford, C. C., Goldstein, J., Lisak, R. P., Myers, L. W., Panitch, H. S., Rose, J. W., Schiffer, R. B., et al. (1995) · Neurology · doi:10.1212/wnl.45.7.1268 · Cited by 1,898
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Gold, R., Kappos, L., Arnold, D. L., Bar-Or, A., Giovannoni, G., Selmaj, K., Tornatore, C., Sweetser, M. T., Yang, M., Sheikh, S. I., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114287 · Cited by 1,733
Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists
Mandala, S., Hajdu, R., Bergstrom, J., Quackenbush, E., Xie, J., Milligan, J., Thornton, R., Shei, G.-J., Card, D., Keohane, C., et al. (2002) · Science · doi:10.1126/science.1070238 · Cited by 1,690
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Fox, R. J., Miller, D. H., Phillips, J. T., Hutchinson, M., Havrdova, E., Kita, M., Yang, M., Raghupathi, K., Novas, M., Sweetser, M. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206328 · Cited by 1,355
Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis
Rudick, R. A., Stuart, W. H., Calabresi, P. A., Confavreux, C., Galetta, S. L., Radue, E.-W., Lublin, F. D., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044396 · Cited by 1,344
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
Bloomgren, G., Richman, S., Hotermans, C., Subramanyam, M., Goelz, S., Natarajan, A., Lee, S., Plavina, T., Scanlon, J. V., Sandrock, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1107829 · Cited by 1,242
Cohen, J. A., Coles, A. J., Arnold, D. L., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., Fisher, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61769-3 · Cited by 1,205
Self-citationColes, A. J., Twyman, C. L., Arnold, D. L., Cohen, J. A., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61768-1 · Cited by 1,198
Self-citationGirard, M., Duquette, P., & Sibley, W. A. (1993) · Cited by 1,196
Linker, R. A., Lee, D.-H., Ryan, S., van Dam, A. M., Conrad, R., Bista, P., Zeng, W., Hronowsky, X., Buko, A., Chollate, S., et al. (2011) · Brain · doi:10.1093/brain/awq386 · Cited by 1,155
Pathological mechanisms in progressive multiple sclerosis
Mahad, D. H., Trapp, B. D., & Lassmann, H. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70256-x · Cited by 1,137
Inflammatory cortical demyelination in early multiple sclerosis.
Lucchinetti, C. F., Popescu, B. F. G., Bunyan, R. F., Moll, N. M., Roemer, S. F., Lassmann, H., Brück, W., Parisi, J. E., Scheithauer, B. W., Giannini, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1100648 · Cited by 1,103
Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's Disease
Van Assche, G., Van Ranst, M., Sciot, R., Dubois, B., Vermeire, S., Noman, M., Verbeeck, J., Geboes, K., Robberecht, W., & Rutgeerts, P. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051586 · Cited by 1,060
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802670 · Cited by 1,017
Multiple Sclerosis: Current Knowledge and Future Outlook
Kamm, C. P., Uitdehaag, B. M., & Polman, C. H. (2014) · European Neurology · doi:10.1159/000360528 · Cited by 1,010
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
O'Connor, P., Wolinsky, J. S., Confavreux, C., Comi, G., Kappos, L., Olsson, T. P., Benzerdjeb, H., Truffinet, P., Wang, L., Miller, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014656 · Cited by 990
Pharmacokinetic and biodistribution properties of poly(ethylene glycol)–protein conjugates
Caliceti, P. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(03)00108-x · Cited by 947
Hartung, H.-P., Gonsette, R., Konig, N., Kwiecinski, H., Guseo, A., Morrissey, S. P., Krapf, H., & Zwingers, T. (2002) · The Lancet · doi:10.1016/s0140-6736(02)12023-x · Cited by 946
Self-citationHawker, K., O'Connor, P., Freedman, M. S., Calabresi, P. A., Antel, J., Simon, J., Hauser, S., Waubant, E., Vollmer, T., Panitch, H., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21867 · Cited by 934
Weinshenker, B. G., O'Brien, P. C., Petterson, T. M., Noseworthy, J. H., Lucchinetti, C. F., Dodick, D. W., Pineda, A. A., Stevens, L. N., & Rodriguez, M. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199912)46:6<878::aid-ana10>3.0.co;2-q · Cited by 894
Carson, K. R., Evens, A. M., Richey, E. A., Habermann, T. M., Focosi, D., Seymour, J. F., Laubach, J., Bawn, S. D., Gordon, L. I., Winter, J. N., et al. (2009) · Blood · doi:10.1182/blood-2008-10-186999 · Cited by 866
Kappos, L., Li, D., Calabresi, P. A., O'Connor, P., Bar-Or, A., Barkhof, F., Yin, M., Leppert, D., Glanzman, R., Tinbergen, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61649-8 · Cited by 743
Clifford, D. B., DeLuca, A., Simpson, D. M., Arendt, G., Giovannoni, G., & Nath, A. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70028-4 · Cited by 636
Confavreux, C., O'Connor, P., Comi, G., Freedman, M. S., Miller, A. E., Olsson, T. P., Wolinsky, J. S., Bagulho, T., Delhay, J.-L., Dukovic, D., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70308-9 · Cited by 579
A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia
Yang, S.-K., Hong, M., Baek, J., Choi, H., Zhao, W., Jung, Y., Haritunians, T., Ye, B. D., Kim, K.-J., Park, S. H., et al. (2014) · Nature Genetics · doi:10.1038/ng.3060 · Cited by 549
The Human Polyomavirus, JCV, Uses Serotonin Receptors to Infect Cells
Elphick, G. F., Querbes, W., Jordan, J. A., Gee, G. V., Eash, S., Manley, K., Dugan, A., Stanifer, M., Bhatnagar, A., Kroeze, W. K., et al. (2004) · Science · doi:10.1126/science.1103492 · Cited by 475
Scannevin, R. H., Chollate, S., Jung, M.-Y., Shackett, M., Patel, H., Bista, P., Zeng, W., Ryan, S., Yamamoto, M., Lukashev, M., et al. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.190132 · Cited by 461
Plavina, T., Subramanyam, M., Bloomgren, G., Richman, S., Pace, A., Lee, S., Schlain, B., Campagnolo, D., Belachew, S., & Ticho, B. (2014) · Annals of Neurology · doi:10.1002/ana.24286 · Cited by 438
Keegan, M., König, F., McClelland, R., Brück, W., Morales, Y., Bitsch, A., Panitch, H., Lassmann, H., Weinshenker, B., Rodriguez, M., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67102-4 · Cited by 433
Mechanism of Action for Leflunomide in Rheumatoid Arthritis
Fox, R. I., Herrmann, M. L., Frangou, C. G., Wahl, G. M., Morris, R. E., Strand, V., & Kirschbaum, B. J. (1999) · Clinical Immunology · doi:10.1006/clim.1999.4777 · Cited by 420
Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists
Stahn, C., Löwenberg, M., Hommes, D. W., & Buttgereit, F. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.05.019 · Cited by 419
Calabresi, P. A., Kieseier, B. C., Arnold, D. L., Balcer, L. J., Boyko, A., Pelletier, J., Liu, S., Zhu, Y., Seddighzadeh, A., Hung, S., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70068-7 · Cited by 398
Interferons and viral infections
Fensterl, V., & Sen, G. C. (2009) · BioFactors · doi:10.1002/biof.6 · Cited by 396
Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis
Cohen, J. A., & Chun, J. (2011) · Annals of Neurology · doi:10.1002/ana.22426 · Cited by 393
van Vollenhoven, R. F., Emery, P., Bingham, C. O., Keystone, E. C., Fleischmann, R. M., Furst, D. E., Tyson, N., Collinson, N., & Lehane, P. B. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201956 · Cited by 390
A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses
O’Connor, P. W., Li, D., Freedman, M. S., Bar-Or, A., Rice, G. P. A., Confavreux, C., Paty, D. W., Stewart, J. A., & Scheyer, R. (2006) · Neurology · doi:10.1212/01.wnl.0000203121.04509.31 · Cited by 358
Teriflunomide and Its Mechanism of Action in Multiple Sclerosis
Bar-Or, A., Pachner, A., Menguy-Vacheron, F., Kaplan, J., & Wiendl, H. (2014) · Drugs · doi:10.1007/s40265-014-0212-x · Cited by 356
Anti-α4 integrin therapy for multiple sclerosis: Mechanisms and rationale
Rice, G. P. A., Hartung, H.-P., & Calabresi, P. A. (2005) · Neurology · doi:10.1212/01.wnl.0000158329.30470.d0 · Cited by 305
Self-citationSecondary immunodeficiencies, including HIV infection
Chinen, J., & Shearer, W. T. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.08.040 · Cited by 305
Therapeutic Plasma Exchange: Complications and Management
Mokrzycki, M. H., & Kaplan, A. A. (1994) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)80135-1 · Cited by 303
Wynn, D., Kaufman, M., Montalban, X., Vollmer, T., Simon, J., Elkins, J., O'Neill, G., Neyer, L., Sheridan, J., Wang, C., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70033-8 · Cited by 301
Miller, A. E., Wolinsky, J. S., Kappos, L., Comi, G., Freedman, M. S., Olsson, T. P., Bauer, D., Benamor, M., Truffinet, P., & O'Connor, P. W. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70191-7 · Cited by 300
Jones, J. L., Phuah, C.-L., Cox, A. L., Thompson, S. A., Ban, M., Shawcross, J., Walton, A., Sawcer, S. J., Compston, A., & Coles, A. J. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37878 · Cited by 297
Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis
Cox, A. L., Thompson, S. A. J., Jones, J. L., Robertson, V. H., Hale, G., Waldmann, H., Compston, D. A. S., & Coles, A. J. (2005) · European Journal of Immunology · doi:10.1002/eji.200535075 · Cited by 291
Gold, R., Giovannoni, G., Selmaj, K., Havrdova, E., Montalban, X., Radue, E.-W., Stefoski, D., Robinson, R., Riester, K., Rana, J., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)62190-4 · Cited by 287
Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: A phase 2 study
Sorensen, P. S., Lisby, S., Grove, R., Derosier, F., Shackelford, S., Havrdova, E., Drulovic, J., & Filippi, M. (2014) · Neurology · doi:10.1212/wnl.0000000000000125 · Cited by 278
Ziemssen, T. (2002) · Brain · doi:10.1093/brain/awf252 · Cited by 268
Fingolimod (FTY720) Enhances Remyelination Following Demyelination of Organotypic Cerebellar Slices
Miron, V. E., Ludwin, S. K., Darlington, P. J., Jarjour, A. A., Soliven, B., Kennedy, T. E., & Antel, J. P. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.091234 · Cited by 267
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
Kappos, L., Wiendl, H., Selmaj, K., Arnold, D. L., Havrdova, E., Boyko, A., Kaufman, M., Rose, J., Greenberg, S., Sweetser, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501481 · Cited by 265
Hong, J., Li, N., Zhang, X., Zheng, B., & Zhang, J. Z. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502187102 · Cited by 264
Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy
Tuohy, O., Costelloe, L., Hill-Cawthorne, G., Bjornson, I., Harding, K., Robertson, N., May, K., Button, T., Azzopardi, L., Kousin-Ezewu, O., et al. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-307721 · Cited by 238
Sørensen, P. S., Bertolotto, A., Edan, G., Giovannoni, G., Gold, R., Havrdova, E., Kappos, L., Kieseier, B. C., Montalban, X., & Olsson, T. (2012) · Multiple Sclerosis Journal · doi:10.1177/1352458511435105 · Cited by 237
Identification and Characterization of Mefloquine Efficacy against JC Virus In Vitro
Brickelmaier, M., Lugovskoy, A., Kartikeyan, R., Reviriego-Mendoza, M. M., Allaire, N., Simon, K., Frisque, R. J., & Gorelik, L. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01614-08 · Cited by 234
Marriott, J. J., Miyasaki, J. M., Gronseth, G., & O'Connor, P. W. (2010) · Neurology · doi:10.1212/wnl.0b013e3181dc1ae0 · Cited by 233
B-Cell Reconstitution and BAFF After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis
Thompson, S. A. J., Jones, J. L., Cox, A. L., Compston, D. A. S., & Coles, A. J. (2010) · Journal of Clinical Immunology · doi:10.1007/s10875-009-9327-3 · Cited by 232
Pathology and disease mechanisms in different stages of multiple sclerosis
Lassmann, H. (2013) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2013.05.010 · Cited by 224
McGuigan, C., Craner, M., Guadagno, J., Kapoor, R., Mazibrada, G., Molyneux, P., Nicholas, R., Palace, J., Pearson, O. R., Rog, D., et al. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-311100 · Cited by 221
Three times weekly glatiramer acetate in relapsing–remitting multiple sclerosis
Khan, O., Rieckmann, P., Boyko, A., Selmaj, K., Zivadinov, R., & GALA Study Group (2013) · Annals of Neurology · doi:10.1002/ana.23938 · Cited by 219
Overview of azathioprine treatment in multiple sclerosis
Yudkin, P. L., Ellison, G. W., Ghezzi, A., Goodkin, D. E., Hughes, R. A. C., McPherson, K., Mertin, J., & Milanese, C. (1991) · The Lancet · doi:10.1016/0140-6736(91)91909-e · Cited by 219
Xia, M. Q., Hale, G., Lifely, M. R., Ferguson, M. A. J., Campbell, D., Packman, L., & Waldmann, H. (1993) · Biochemical Journal · doi:10.1042/bj2930633 · Cited by 213
Multiple Sclerosis Therapy Consensus Group (MSTCG), Wiendl, H., Toyka, K. V., Rieckmann, P., Gold, R., Hartung, H.-P., & Hohlfeld, R. (2008) · Journal of Neurology · doi:10.1007/s00415-008-0061-1 · Cited by 212
Self-citationTony, H.-P., Burmester, G., Schulze-Koops, H., Grunke, M., Henes, J., Kötter, I., Haas, J., Unger, L., Lovric, S., Haubitz, M., et al. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3337 · Cited by 212
Self-citationTreatment Optimization in MS: Canadian MS Working Group Updated Recommendations
Freedman, M. S., Selchen, D., Arnold, D. L., Prat, A., Banwell, B., Yeung, M., Morgenthau, D., & Lapierre, Y. (2013) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100014244 · Cited by 202
Immune Surveillance of the CNS following Infection and Injury
Russo, M. V., & McGavern, D. B. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.08.002 · Cited by 191
Molloy, E. S., & Calabrese, L. H. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34468 · Cited by 191
Dixon, W. G., Suissa, S., & Hudson, M. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3453 · Cited by 190
PML in a Patient with Lymphocytopenia Treated with Dimethyl Fumarate
Rosenkranz, T., Novas, M., & Terborg, C. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1415408 · Cited by 188
Reduction of CD8 + T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate
Spencer, C. M., Crabtree-Hartman, E. C., Lehmann-Horn, K., Cree, B. A. C., & Zamvil, S. S. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000076 · Cited by 187
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis
Filippini, G., Del Giovane, C., Vacchi, L., D'Amico, R., Di Pietrantonj, C., Beecher, D., & Salanti, G. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008933.pub2 · Cited by 186
Le Page, E., Veillard, D., Laplaud, D. A., Hamonic, S., Wardi, R., Lebrun, C., Zagnoli, F., Wiertlewski, S., Deburghgraeve, V., Coustans, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61137-0 · Cited by 185
PML in a Patient Treated with Dimethyl Fumarate from a Compounding Pharmacy
van Oosten, B. W., Killestein, J., Barkhof, F., Polman, C. H., & Wattjes, M. P. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1215357 · Cited by 185
Arvin, A. M., Wolinsky, J. S., Kappos, L., Morris, M. I., Reder, A. T., Tornatore, C., Gershon, A., Gershon, M., Levin, M. J., Bezuidenhoudt, M., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.3065 · Cited by 182
INFECTIONS ASSOCIATED WITH STEROID USE
Klein, N. C., Go, C. H.-U., & Cunha, B. A. (2001) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(05)70154-9 · Cited by 176
Havrdova, E., Horakova, D., & Kovarova, I. (2015) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285614563522 · Cited by 176
The Immunomodulator FTY720 Has a Direct Cytoprotective Effect in Oligodendrocyte Progenitors
Coelho, R. P., Payne, S. G., Bittman, R., Spiegel, S., & Sato-Bigbee, C. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.123927 · Cited by 175
Gold, R., Linker, R. A., & Stangel, M. (2012) · Clinical Immunology · doi:10.1016/j.clim.2011.02.017 · Cited by 170
Fingolimod is a potential novel therapy for multiple sclerosis
Aktas, O., Küry, P., Kieseier, B., & Hartung, H.-P. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.76 · Cited by 167
Self-citationPML in a Patient without Severe Lymphocytopenia Receiving Dimethyl Fumarate
Nieuwkamp, D. J., Murk, J., Cremers, C. H. P., Killestein, J., Viveen, M. C., Hecke, W. V., Frijlink, D. W., Wattjes, M. P., & van Oosten, B. W. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1413724 · Cited by 164
Mitoxantrone for multiple sclerosis
Martinelli Boneschi, F., Vacchi, L., Rovaris, M., Capra, R., & Comi, G. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002127.pub3 · Cited by 156
The Pharmacology of Azathioprine
Elion, G. B. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb35897.x · Cited by 156
The structure and function of the S1P1 receptor
O'Sullivan, C., & Dev, K. K. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.05.002 · Cited by 151
Azathioprine for multiple sclerosis
Casetta, I., Iuliano, G., & Filippini, G. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003982.pub2 · Cited by 150
Phosphorylated FTY720 promotes astrocyte migration through sphingosine‐1‐phosphate receptors
Mullershausen, F., Craveiro, L. M., Shin, Y., Cortes‐Cros, M., Bassilana, F., Osinde, M., Wishart, W. L., Guerini, D., Thallmair, M., Schwab, M. E., et al. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04629.x · Cited by 140
Confavreux, C., Li, D. K., Freedman, M. S., Truffinet, P., Benzerdjeb, H., Wang, D., Bar-Or, A., Traboulsee, A. L., Reiman, L. E., O’Connor, P. W., et al. (2012) · Multiple Sclerosis Journal · doi:10.1177/1352458512436594 · Cited by 140
Persistence and pathogenesis of the neurotropic polyomavirus JC
Wollebo, H. S., White, M. K., Gordon, J., Berger, J. R., & Khalili, K. (2015) · Annals of Neurology · doi:10.1002/ana.24371 · Cited by 134
Warnke, C., Menge, T., Hartung, H., Racke, M. K., Cravens, P. D., Bennett, J. L., Frohman, E. M., Greenberg, B. M., Zamvil, S. S., Gold, R., et al. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.161 · Cited by 130
Self-citationOutcome and survival of asymptomatic PML in natalizumab‐treated MS patients
Dong‐Si, T., Richman, S., Wattjes, M. P., Wenten, M., Gheuens, S., Philip, J., Datta, S., McIninch, J., Bozic, C., Bloomgren, G., et al. (2014) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.114 · Cited by 129
Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings
Kappos, L., Cohen, J. A., Collins, W., de Vera, A., Zhang-Auberson, L., Ritter, S., von Rosenstiel, P., & Francis, G. (2014) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2014.03.002 · Cited by 125
Fidler, J. M., DeJoy, S. Q., & Gibbons, J. J. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.137.2.727 · Cited by 124
Interfer beta augments supperssor cell function in multiple sclerosis
Noronha, A., Toscas, A., & Jensen, M. A. (1990) · Annals of Neurology · doi:10.1002/ana.410270219 · Cited by 121
Özenci, V., Kouwenhoven, M. C. M., Huang, Y.-M., Kivisäkk, P., & Link, H. (2000) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2000.01175.x · Cited by 120
A Novel PEGylated Interferon Beta‐1a for Multiple Sclerosis: Safety, Pharmacology, and Biology
Hu, X., Miller, L., Richman, S., Hitchman, S., Glick, G., Liu, S., Zhu, Y., Crossman, M., Nestorov, I., Gronke, R. S., et al. (2012) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011407068 · Cited by 118
Xie, J., Nomura, N., Koprak, S., Quackenbush, E. J., Forrest, M. J., & Rosen, H. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.7.3662 · Cited by 116
Saylor, D. R., & McArthur, J. C. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.557 · Cited by 114
Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein.
Teitelbaum, D., Milo, R., Arnon, R., & Sela, M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.1.137 · Cited by 112
Promiscuous Binding of Synthetic Copolymer 1 to Purified HLA-DR Molecules
Fridkis-Hareli, M., & Strominger, J. L. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.9.4386 · Cited by 111
Alemtuzumab: A new therapy for active relapsing–remitting multiple sclerosis
Hartung, H., Aktaş, O., & Boyко, A. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458514549398 · Cited by 110
Self-citationAlemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort
Willis, M., Harding, K. E., Pickersgill, T. P., Wardle, M., Pearson, O. R., Scolding, N. J., Smee, J., & Robertson, N. P. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458515614092 · Cited by 108
Immune-mediated CNS diseases: A review on nosological classification and clinical features
Zettl, U. K., Stüve, O., & Patejdl, R. (2011) · Autoimmunity Reviews · doi:10.1016/j.autrev.2011.05.008 · Cited by 108
Self-citationExogenous and endogenous glucocorticoids in rheumatic diseases
Buttgereit, F., Burmester, G., Straub, R. H., Seibel, M. J., & Zhou, H. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30070 · Cited by 105
Khouri, R., Báfica, A. L. B., da Silva, M. D. P. P., Noronha, A., Kolb, J., Wietzerbin, J., Barral, A. M. P., Barral‐Netto, M., & Weyenbergh, J. V. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802860 · Cited by 103
Aktaş, O., Kieseier, B. C., & Hartung, H. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2009.12.002 · Cited by 102
Self-citationVaccination against infection in patients with multiple sclerosis
Loebermann, M., Winkelmann, A., Hartung, H., Hengel, H., Reisinger, E. C., & Zettl, U. K. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.8 · Cited by 102
Self-citationFine, A. J., Sorbello, A. F., Kortepeter, C. M., & Scarazzini, L. J. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit376 · Cited by 101
Dong‐Si, T., Gheuens, S., Gangadharan, A., Wenten, M., Philip, J., McIninch, J., Datta, S., Richert, N. D., Bozic, C. M., Bloomgren, G., et al. (2015) · Journal of NeuroVirology · doi:10.1007/s13365-015-0316-4 · Cited by 100
Manufacturer's Response to Case Reports of PML
Sweetser, M. T., Dawson, K. T., & Bozic, C. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1300283 · Cited by 99
Oral treatment for multiple sclerosis
Killestein, J., Rudick, R. A., & Polman, C. H. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70228-9 · Cited by 98
The Role of Natural Killer Cells in Multiple Sclerosis and Their Therapeutic Implications
Chanvillard, C., Jacolik, R., Infante‐Duarte, C., & Nayak, R. C. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00063 · Cited by 97
Consumption of Raw or Unpasteurized Milk and Milk Products by Pregnant Women and Children
Brady, M. T., Byington, C. L., Davies, H. D., Edwards, K. M., Glodé, M. P., Jackson, M. A., KEYSERLING, H. L., Maldonado, Y., Murray, D. L., Orenstein, W. A., et al. (2013) · PEDIATRICS · doi:10.1542/peds.2013-3502 · Cited by 96
Treatment of Progressive Multifocal Leukoencephalopathy With Interleukin 7
Alstadhaug, K. B., Croughs, T., Henriksen, S., Leboeuf, C., Sereti, I., Hirsch, H. H., & Rinaldo, C. H. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.825 · Cited by 94
Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis
Lanini, S., Molloy, A., Fine, P., Prentice, A. G., Ippolito, G., & Kibbler, C. C. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-36 · Cited by 91
Mechanisms of Glucocorticoids in the Control of Neuroinflammation
Schweingruber, N., Reichardt, S. D., Lühder, F., & Reichardt, H. M. (2012) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2011.02161.x · Cited by 89
Plasma exchange and intravenous immunoglobulins: Mechanism of action in immune-mediated neuropathies
Lehmann, H. C., & Hartung, H. (2010) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2010.09.015 · Cited by 82
Self-citationGetting specific: monoclonal antibodies in multiple sclerosis
Lutterotti, A., & Martinꝉ, R. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70110-8 · Cited by 82
Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis—Report of Two Cases
Rau, D., Lang, M., Harth, A., Naumann, M. K., Weber, F., Tumani, H., & Bayas, A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160714669 · Cited by 81
Complications of Plasma Exchange in Neurological Patients
Rodnitzky, R. L., & Goeken, J. A. (1982) · Archives of Neurology · doi:10.1001/archneur.1982.00510180028007 · Cited by 81
Safety with Ocrelizumab in Rheumatoid Arthritis: Results from the Ocrelizumab Phase III Program
Emery, P., Rigby, W., Tak, P. P., Dörner, T., Olech, E., Martin, C., Millar, L., Travers, H., & Fisheleva, E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087379 · Cited by 81
Bouget, J., Chevret, S., Chastang, C., & Raphaël, J.-C. (1993) · Critical Care Medicine · doi:10.1097/00003246-199305000-00006 · Cited by 76
Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI
Wattjes, M. P., & Barkhof, F. (2014) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000099 · Cited by 74
Mechanisms of action of interferon-? in multiple sclerosis
Arnason, B. G. W., Dayal, A. S., Qu, Z. X., Jensen, M. A., Gen�, K., & Reder, A. T. (1996) · Springer Seminars in Immunopathology · doi:10.1007/bf00792613 · Cited by 74
Rituximab for relapsing-remitting multiple sclerosis
He, D., Guo, R. C., Zhang, F., Zhang, C., Dong, S., & Zhou, H. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009130.pub3 · Cited by 73
Protection against Progressive Leishmaniasis by IFN-β
Mattner, J., Wandersee-Steinhäuser, A., Pahl, A., Röllinghoff, M., Majeau, G. R., Hochman, P. S., & Bogdan, C. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.12.7574 · Cited by 66
Hundeshagen, A., Hecker, M., Paap, B. K., Angerstein, C., Kandulski, O., Fatum, C., Hartmann, C., Koczan, D., Thiesen, H., & Zettl, U. K. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-140 · Cited by 65
Self-citationOpportunistic infections and other risks with newer multiple sclerosis therapies
Berger, J. R., & Houff, S. A. (2009) · Annals of Neurology · doi:10.1002/ana.21630 · Cited by 62
Type I interferon dysregulation and neurological disease
McGlasson, S. L., Jury, A., Jackson, A. P., & Hunt, D. P. J. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.143 · Cited by 62
Progressive multifocal leukoencephalopathy in patients with multiple sclerosis
Baldwin, K., & Hogg, J. P. (2013) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328360279f · Cited by 60
Reprogramming the immune repertoire with alemtuzumab in MS
Wiendl, H., & Kieseier, B. C. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.2 · Cited by 59
Azathioprine for multiple sclerosis
Casetta, I., Iuliano, G., & Filippini, G. (2009) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.144972 · Cited by 59
Pharmacology of glucocorticoids in rheumatoid arthritis
Spies, C. M., Bijlsma, J. W. J., Burmester, G. R., & Buttgereit, F. (2010) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2010.02.001 · Cited by 58
Progressive multifocal leukoencephalopathy after natalizumab discontinuation
Fine, A. J., Sorbello, A. F., Kortepeter, C. M., & Scarazzini, L. J. (2013) · Annals of Neurology · doi:10.1002/ana.24051 · Cited by 57
Biologics in children’s autoimmune disorders: efficacy and safety
Breda, L., Torto, M. D., Sanctis, S. D., & Chiarelli, F. (2010) · European Journal of Pediatrics · doi:10.1007/s00431-010-1238-z · Cited by 57
Yushchenko, M., M�der, M., Elitok, E., Bitsch, A., Dressel, A., Tumani, H., Bogumil, T., Kitze, B., Poser, S., & Weber, F. (2003) · Journal of Neurology · doi:10.1007/s00415-003-0191-4 · Cited by 55
Isidoro, L., Pires, P., Rito, L., & Cordeiro, G. (2014) · BMJ Case Reports · doi:10.1136/bcr-2013-201781 · Cited by 55
Leussink, V. I., Zettl, U. K., Jander, S., Pepinsky, R. B., Lobb, R. R., Stoll, G., Toyka, K. V., & Gold, R. (2002) · Acta Neuropathologica · doi:10.1007/s004010100444 · Cited by 54
Self-citationAlemtuzumab: The advantages and challenges of a novel therapy in MS
Menge, T., Stüve, O., Kieseier, B. C., & Hartung, H.-P. (2014) · Neurology · doi:10.1212/wnl.0000000000000540 · Cited by 53
Self-citationManaging the risks of immunosuppression
Riminton, D. S., Hartung, H.-P., & Reddel, S. W. (2011) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328346d47d · Cited by 50
Self-citationMontalbán, X., Hemmer, B., Rammohan, K. W., Giovannoni, G., Seze, J. D., Bar‐Or, A., Arnold, D. L., Sauter, A., Kakarieka, A., Masterman, D. L., et al. (2015) · mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) · Cited by 50
Mechanisms of action of interferon-β in multiple sclerosis
Arnason, B. G. W., Dayal, A. S., Qu, Z. X., Jensen, M. A., Genç, K., & Reder, A. T. (1996) · Springer eBooks · doi:10.1007/978-3-642-61191-9_18 · Cited by 49
Monaco, M. C., & Major, E. O. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00159 · Cited by 49
Waggoner, J. J., Martinu, T., & Palmer, S. M. (2009) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2008.12.010 · Cited by 48
Boster, A. L., Bartoszek, M. P., O’Connell, C. M., Pitt, D., & Racke, M. K. (2011) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285611422108 · Cited by 47
GRAID investigators, Rommer, P. S., Dörner, T., Freivogel, K., Haas, J., Kieseier, B. C., Kümpfel, T., Paul, F., Proft, F. N., Schulze‐Koops, H., et al. (2015) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-015-9646-5 · Cited by 45
Self-citationDaclizumab (anti-CD25) in multiple sclerosis
Pfender, N., & Martinꝉ, R. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.04.015 · Cited by 44
Hecker, M., Goertsches, R. H., Fatum, C., Koczan, D., Thiesen, H., Guthke, R., & Zettl, U. K. (2010) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.77 · Cited by 44
Self-citationChahin, S., & Berger, J. R. (2014) · Journal of NeuroVirology · doi:10.1007/s13365-014-0303-1 · Cited by 43
Cerebellar manifestation of PML under fumarate and after efalizumab treatment of psoriasis
Stoppe, M., Thoma, E., Liebert, U. G., Major, E. O., Hoffmann, K., Claßen, J., & Bergh, F. T. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7311-1 · Cited by 41
Cryptococcal meningitis in a multiple sclerosis patient taking natalizumab
Valenzuela, R. M., Pula, J. H., Garwacki, D. J., Cotter, J. G., & Kattah, J. C. (2014) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2014.03.007 · Cited by 40
Immunological risk factors for infection after immunosuppressive and biologic therapies
Carbone, J., del Pozo, N., Gallego, A., & Sarmiento, E. (2011) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.10.178 · Cited by 40
JC Polyomavirus Granule Cell Neuronopathy in a Patient Treated With Rituximab
Dang, L. T., Dang, X., Koralnik, I. J., & Todd, P. K. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.4668 · Cited by 36
Recent advances in treating multiple sclerosis: efficacy, risks and place in therapy
Jeffery, D. (2012) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622312466279 · Cited by 35
Martin, S. T., Cardwell, S. M., Nailor, M. D., & Gabardi, S. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12649 · Cited by 34
Correale, J. D., Abad, P., Alvarenga, R. M. P., Alves‐Leon, S. V., Armas, E., Barahona, J., Buzó, R., Corona, T., Cristiano, E., Gracia, F., et al. (2014) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2014.02.017 · Cited by 34
Safety of plasmapheresis in the treatment of neurological disease
Vucic, S., & Davies, L. (1998) · Australian and New Zealand Journal of Medicine · doi:10.1111/j.1445-5994.1998.tb01952.x · Cited by 33
Synthesis of novel therapeutic agents for the treatment of multiple sclerosis: A brief overview
Mulakayala, N., Rao, P., Javed Iqbal, M., Bandichhor, R., & Oruganti, S. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.10.055 · Cited by 33
Neurological immune reconstitution inflammatory response: riding the tide of immune recovery
Clifford, D. B. (2015) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000200 · Cited by 33
Ebers, G. C. (1998) · Cited by 33
A fresh look at glucocorticoids how to use an old ally more effectively.
Buttgereit, F. (2012) · PubMed · Cited by 28
Mitoxantrone repression of astrocyte activation: Relevance to multiple sclerosis
Burns, S. A., ARCHER, R. L., Chavis, J. A., Tull, C. A., Hensley, L. L., & Drew, P. D. (2012) · Brain Research · doi:10.1016/j.brainres.2012.07.054 · Cited by 26
Broadley, S., Barnett, M. H., Boggild, M., Brew, B. J., Butzkueven, H., Heard, R. N., Hodgkinson, S. J., Kermode, A. G., Lechner‐Scott, J., Macdonell, R. A. L., et al. (2014) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2014.01.017 · Cited by 24
Montalbán, X., Hemmer, B., Rammohan, K. W., Giovannoni, G., Seze, J. D., Bar‐Or, A., Arnold, D. L., Sauter, A., Masterman, D. L., da Fontoura, P. P., et al. (2016) · Neurology · doi:10.1212/wnl.86.16_supplement.s49.001 · Cited by 24
Ehler, J., Koball, S., Sauer, M., Hickstein, H., Mitzner, S. R., Benecke, R., & Zettl, U. K. (2014) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.12176 · Cited by 21
Self-citationKohlmann, R., Salmen, A., Chan, A., Knabbe, C., Diekmann, J., Brockmeyer, N. H., Skaletz‐Rorowski, A., Michalik, C., Gold, R., & Überla, K. (2015) · Multiple Sclerosis Journal · doi:10.1177/1352458515576984 · Cited by 19
Pirko, I., & Rodriguez, M. (2004) · Archives of Neurology · doi:10.1001/archneur.61.7.1148 · Cited by 17
Progressive multifocal leukoencephalopathy after natalizumab discontinuation: Few and true?
Wattjes, M. P., & Killestein, J. (2014) · Annals of Neurology · doi:10.1002/ana.24110 · Cited by 16
Two cases of opportunistic parasite infections in patients receiving alemtuzumab
Désoubeaux, G., Caumont, C., Passot, C., Dartigeas, C., Bailly, É., Chandenier, J., & Duong, T. H. (2011) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2011-200403 · Cited by 15
An Overview of Infectious Complications in Children on New Biologic Response-Modifying Agents
Abinun, M. (2010) · Pediatric Health · doi:10.2217/phe.10.57 · Cited by 12
Rao, H., Wei, L., Li, J., Zhang, L., Chen, H., Zhu, L.-M., Liu, F., Sun, Y., & Wang, H. (2009) · PubMed · Cited by 12
Spinal cord pathology in multiple sclerosis
Lassmann, H. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70037-2 · Cited by 9
Bongioanni, P., Lombardo, F. P., Moscato, G., Mosti, S., & Meucci, G. (1999) · Archives of Neurology · doi:10.1001/archneur.56.2.217 · Cited by 7
Maffione, A. B., Tatò, E., Losito, S., Nacci, C., Mitolo, V., Troiano, M., Ruggieri, M., Livrea, P., & Jirillo, E. (2000) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923970009016402 · Cited by 7
Mader, E. C., Richeh, W., Maury, J. S., Sullivan, L. L., Gutierrez, A., & Lovera, J. F. (2015) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2014.12.034 · Cited by 4
Loebermann, M., Reisinger, E. C., Zettl, U. K., & Winkelmann, A. (2014) · Nervenheilkunde · doi:10.1055/s-0038-1627755 · Cited by 3
Self-citation
Cited by
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
Hauser, S. L., Bar-Or, A., Comi, G., Giovannoni, G., Hartung, H.-P., Hemmer, B., Lublin, F., Montalban, X., Rammohan, K. W., Selmaj, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1601277 · Cited by 2,021
Self-citationECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
Montalban, X., Gold, R., Thompson, A. J., Otero-Romero, S., Amato, M. P., Chandraratna, D., Clanet, M., Comi, G., Derfuss, T., Fazekas, F., et al. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458517751049 · Cited by 712
Self-citationLuna, G., Alping, P., Burman, J., Fink, K., Fogdell-Hahn, A., Gunnarsson, M., Hillert, J., Langer-Gould, A., Lycke, J., Nilsson, P., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2019.3365 · Cited by 521
“Participants were considered at risk for infections from the start date of treatment (for the matched general population participants, the date of the matched patient’s treatment start was used) until the first of (1) 90 days after recorded discontinuation of therapy, (2) death, (3) emigration from Sweden, (4) the out…”
MethodDisease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis
Sormani, M. P., De Rossi, N., Schiavetti, I., Carmisciano, L., Cordioli, C., Moiola, L., Radaelli, M., Immovilli, P., Capobianco, M., Trojano, M., et al. (2021) · Annals of Neurology · doi:10.1002/ana.26028 · Cited by 447
Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis
Rotstein, D., & Montalban, X. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0170-8 · Cited by 289
Metadata
- Authors
- Winkelmann, A., Loebermann, M., Reisinger, E. C., Hartung, H.-P., & Zettl, U. K.
- Venue
- Nature Reviews Neurology
- Published
- 2016-03-04
- Volume
- 12
- Issue
- 4
- Pages
- 217-233
- ISSN
- 1759-4758 (ISSN-L)
- 1759-4766
- OpenAlex
- W2327614140
- Cited by
- 254
- References
- 184
- FWCI
- 4.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.